Compare NTR & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTR | ONC |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | Canada | Switzerland |
| Employees | N/A | 12000 |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2B | 40.6B |
| IPO Year | 2018 | 2015 |
| Metric | NTR | ONC |
|---|---|---|
| Price | $67.18 | $359.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 10 |
| Target Price | $75.45 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 2.3M | 413.2K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | N/A | ★ 140.43 |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $238,387,000.00 |
| Revenue This Year | $4.03 | $723.76 |
| Revenue Next Year | N/A | $15.04 |
| P/E Ratio | ★ $18.99 | $1,158.94 |
| Revenue Growth | N/A | ★ 22179.16 |
| 52 Week Low | $53.03 | $253.95 |
| 52 Week High | $85.36 | $385.22 |
| Indicator | NTR | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 48.88 | 75.74 |
| Support Level | $58.83 | $305.66 |
| Resistance Level | $70.10 | $371.94 |
| Average True Range (ATR) | 1.85 | 7.63 |
| MACD | -0.25 | 3.03 |
| Stochastic Oscillator | 40.44 | 84.69 |
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients—nitrogen, potash, and phosphate—although its main focus is potash, where it is the global leader in installed capacity with a roughly 20% market share. The company is also the largest agricultural retailer in North America and Australia, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.